Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 11/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.32 |
| ▸ | GAK | O14976 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184527 | 0.78 | EGFR (0.50) | EGFRERBB2GAK | |
| SCHEMBL3188849 | 0.73 | SRC (0.40) | L3MBTL1HPGD | |
| SCHEMBL13481315 | 0.71 | KDR (0.36) | L3MBTL1MEN1KMT2A | |
| SCHEMBL13480943 | 0.70 | SRC (0.44) | — | |
| SCHEMBL3189826 | 0.70 | KDR (0.42) | — | |
| SCHEMBL3184768 | 0.70 | KDR (0.36) | — | |
| SCHEMBL21206896 | 0.68 | KDR (0.34) | KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL6384039 | 0.67 | EGFR (0.61) | EGFRERBB2GAK | |
| SCHEMBL3192149 | 0.67 | EGFR (0.50) | EGFRERBB2MAPTMEN1KMT2A | |
| SCHEMBL13481394 | 0.67 | SYK (0.35) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | PRKACA, PRKCE, MAP3K9 | TYMS 694/4885EGFR 991/4885AR 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.